{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:46:17Z","timestamp":1782168377536,"version":"3.54.5"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01030","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T04:34:36Z","timestamp":1527136476000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients"],"prefix":"10.3389","volume":"9","author":[{"given":"Olivier","family":"Gaudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vannina","family":"Seta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9r\u00f4me","family":"Bohelay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Aucouturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mignot-Grootenboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bernardeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Mellottee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Prost-Squarcioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/archderm.134.9.1075","article-title":"Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group","volume":"134","author":"Vaillant","year":"1998","journal-title":"Arch Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0923-1811(97)00067-4","article-title":"Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid","volume":"17","author":"Murakami","year":"1998","journal-title":"J Dermatol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/archderm.1996.03890270044006","article-title":"Drugs associated with bullous pemphigoid. A case-control study","volume":"132","author":"Bastuji-Garin","year":"1996","journal-title":"Arch Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases","volume":"34","author":"Pasmatzi","year":"2011","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin: bullous pemphigoid and dipeptidyl peptidase-IV inhibitors","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamadermatol.2013.1073","article-title":"A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors","volume":"149","author":"Aouidad","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature","volume":"31","author":"Attaway","year":"2014","journal-title":"J Dermatol Case Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/fcp.12083","article-title":"Bullous pemphigoid induced by vildagliptin: a report of three cases","volume":"29","author":"B\u00e9n\u00e9","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Bullous pemphigoid associated with linagliptin treatment","volume":"152","author":"Haber","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000443330","article-title":"Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors \u2013 one due to linagliptin","volume":"232","author":"Mendon\u00e7a","year":"2016","journal-title":"Dermatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/15569527.2016.1211670","article-title":"A case of bullous pemphigoid induced by vildagliptin","volume":"36","author":"Keseroglu","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjd.15111","article-title":"Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180","volume":"176","author":"Sakai","year":"2017","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaad.2017.09.051","article-title":"Detection and characterization of IgG, IgE and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-IV inhibitors","volume":"78","author":"Fania","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000480498","article-title":"Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid","volume":"233","author":"Schaffer","year":"2017","journal-title":"Dermatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jdi.12695","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: report of five cases","volume":"9","author":"Yoshiji","year":"2018","journal-title":"J Diabetes Investig"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.2169\/internalmedicine.8703-16","article-title":"Bullous pemphigoid associated with the dipeptidyl peptidase-4 inhibitor sitagliptin in a patient with liver cirrhosis complicated with rapidly progressive hepatocellular carcinoma","volume":"56","author":"Harada","year":"2017","journal-title":"Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase-IV inhibitors, a risk factor for bullous pemphigoid. Retrospective multicenter case\u2013control study in France and Switzerland","author":"Benzaquen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors: a case\/non-case study in the French Pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish Nationwide Registry Study","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00003226-199105000-00001","article-title":"Systemic chemotherapy for ocular cicatricial pemphigoid","volume":"10","author":"Tauber","year":"1991","journal-title":"Cornea"},{"key":"B28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1046\/j.1365-2133.1998.02168.x","article-title":"Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease","volume":"138","author":"Setterfield","year":"1998","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2133.2009.09566.x","article-title":"Place of human amniotic membrane immunoblotting in the diagnosis of autoimmune bullous dermatoses","volume":"162","author":"Grootenboer-Mignot","year":"2010","journal-title":"Br J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Th\u00e9rapie"},{"key":"B33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2515\/therapie\/2011073","article-title":"R\u00e9actualisation de la m\u00e9thode fran\u00e7aise d\u2019imputabilit\u00e9 des effets ind\u00e9sirables des m\u00e9dicaments","volume":"66","author":"Arimone","year":"2011","journal-title":"Th\u00e9rapie"},{"key":"B34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B35","unstructured":"The Use of the WHO-UMC System for Standardised Case Causality Assessment2017"},{"key":"B36","first-page":"425","article-title":"Diab\u00e8te trait\u00e9: quelles \u00e9volutions entre 2000 et 2009 en France","author":"Ricci","year":"2010","journal-title":"Bull Epidemiol Hebd"},{"key":"B37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/1523-1747.ep12461226","article-title":"Immunoelectron microscopy in subepidermal autoimmune bullous diseases: a prospective study of IgG and C3 bound in vivo in 32 patients","volume":"89","author":"Prost","year":"1987","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/1523-1747.ep12329728","article-title":"Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain","volume":"106","author":"Balding","year":"1996","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/1523-1747.ep12292701","article-title":"Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida","volume":"108","author":"B\u00e9dane","year":"1997","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.4049\/jimmunol.151.10.5742","article-title":"Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain","volume":"151","author":"Giudice","year":"1993","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/BF02505245","article-title":"The majority of bullous pemphigoid and herpes gestationis serum samples react with the NC16a domain of the 180-kDa bullous pemphigoid antigen","volume":"288","author":"Matsumura","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16A protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1523-1747.1999.00497.x","article-title":"IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180","volume":"112","author":"Perriard","year":"1999","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1365-2133.2004.06245.x","article-title":"Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients","volume":"151","author":"Mariotti","year":"2004","journal-title":"Br J Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.0022-202X.2003.22126.x","article-title":"Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients","volume":"122","author":"Di Zenzo","year":"2004","journal-title":"J Invest Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.4049\/jimmunol.176.3.2015","article-title":"Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230","volume":"176","author":"Thoma-Uszynski","year":"2006","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/jid.2011.180","article-title":"Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study","volume":"131","author":"Di Zenzo","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2012.09.012","article-title":"Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbent assay","volume":"68","author":"Fairley","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/bjd.12488","article-title":"Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms","volume":"169","author":"Chanal","year":"2013","journal-title":"Br J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0738-081X(98)00008-X","article-title":"Drug-induced pemphigoid: bullous and cicatricial","volume":"16","author":"Vassileva","year":"1998","journal-title":"Clin Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"B53","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.amjcard.2017.05.009","article-title":"Pharmacologic management of type 2 diabetes mellitus: available therapies","volume":"120","author":"Thrasher","year":"2017","journal-title":"Am J Cardiol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1210\/jc.2004-2460","article-title":"Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed \u03b2-cell function in patients with type 2 diabetes","volume":"90","author":"Mari","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2337\/db07-0136","article-title":"Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes","volume":"56","author":"Vella","year":"2007","journal-title":"Diabetes"},{"key":"B56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14740338.2013.741584","article-title":"Saxagliptin overview: special focus on safety and adverse effects","volume":"12","author":"Ali","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo","volume":"181","author":"Forssmann","year":"2008","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1046\/j.1365-2567.1997.d01-2258.x","article-title":"Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells","volume":"91","author":"Reinhold","year":"1997","journal-title":"Immunology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/sj.jid.5700439","article-title":"Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation","volume":"127","author":"Thielitz","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.jid.5701104","article-title":"Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts","volume":"128","author":"Thielitz","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.2741\/2785","article-title":"Dipeptidyl peptidase IV (DPP IV\/CD26) is a cell-surface plasminogen receptor","volume":"13","author":"Gonzalez-Gronow","year":"2008","journal-title":"Front Biosci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/jid.2008.424","article-title":"Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LABD97","volume":"129","author":"Hofmann","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2249.2011.04464.x","article-title":"Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid","volume":"166","author":"G\u00fcnther","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1172\/JCI23977","article-title":"Synergy between a plasminogen cascade and MMP-9 in autoimmune disease","volume":"115","author":"Liu","year":"2005","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1034\/j.1600-0714.2003.00028.x","article-title":"Cytokine profile and supposed contribution to scarring in cicatricial pemphigoid","volume":"32","author":"Caproni","year":"2003","journal-title":"J Oral Pathol Med"},{"key":"B66","volume-title":"Launch Excellence in the Diabetes Market","year":"2012"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:54:21Z","timestamp":1693684461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2018.01030"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01030","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"article-number":"1030"}}